4FFV
 
 | | Crystal Structure of Dipeptidyl Peptidase IV (DPP4, DPP-IV, CD26) in Complex with 11A19 Fab | | Descriptor: | 11A19 Fab heavy chain, 11A19 Fab light chain, Dipeptidyl peptidase 4 | | Authors: | Wang, Z, Sudom, A, Walker, N.P, Min, X. | | Deposit date: | 2012-06-01 | | Release date: | 2012-12-12 | | Last modified: | 2021-05-19 | | Method: | X-RAY DIFFRACTION (2.4 Å) | | Cite: | An Inhibitory Antibody Against DPP IV Improves Glucose Tolerance in vivo - Validation of Large Molecule Approach for DPP IV Inhibition
To be published
|
|
6PE8
 | | Crystal structure of CD40/ABBV-323 FAB complex | | Descriptor: | FAB Heavy chain, FAB Light chain, SULFATE ION, ... | | Authors: | Argiriadi, M.A. | | Deposit date: | 2019-06-20 | | Release date: | 2019-08-14 | | Last modified: | 2023-10-11 | | Method: | X-RAY DIFFRACTION (2.84 Å) | | Cite: | CD40/anti-CD40 antibody complexes which illustrate agonist and antagonist structural switches.
BMC Mol Cell Biol, 20, 2019
|
|
7U2E
 | | Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing antibody ADI-55688 | | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, ADI-55688 heavy chain, ADI-55688 light chain, ... | | Authors: | Yuan, M, Zhu, X, Wilson, I.A. | | Deposit date: | 2022-02-23 | | Release date: | 2022-05-04 | | Last modified: | 2023-10-25 | | Method: | X-RAY DIFFRACTION (2.85 Å) | | Cite: | A broad and potent neutralization epitope in SARS-related coronaviruses.
Proc.Natl.Acad.Sci.USA, 119, 2022
|
|
7U2D
 | | Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing antibody ADG20 | | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, ADG20 heavy chain, ADG20 light chain, ... | | Authors: | Zhu, X, Yuan, M, Wilson, I.A. | | Deposit date: | 2022-02-23 | | Release date: | 2022-05-04 | | Last modified: | 2023-10-25 | | Method: | X-RAY DIFFRACTION (2.76 Å) | | Cite: | A broad and potent neutralization epitope in SARS-related coronaviruses.
Proc.Natl.Acad.Sci.USA, 119, 2022
|
|
5JXE
 | | Human PD-1 ectodomain complexed with Pembrolizumab Fab | | Descriptor: | Pembrolizumab Fab heavy chain, Pembrolizumab Fab light chain, Programmed cell death protein 1 | | Authors: | Na, Z, Bharath, S.R, Song, H. | | Deposit date: | 2016-05-13 | | Release date: | 2016-08-10 | | Last modified: | 2023-11-08 | | Method: | X-RAY DIFFRACTION (2.9 Å) | | Cite: | Structural basis for blocking PD-1-mediated immune suppression by therapeutic antibody pembrolizumab.
Cell Res., 27, 2017
|
|
7VMZ
 | |
4G3Y
 | | Crystal structure of TNF-alpha in complex with Infliximab Fab fragment | | Descriptor: | Tumor necrosis factor, infliximab Fab H, infliximab Fab L | | Authors: | Liang, S.Y, Dai, J.X, Guo, Y.J, Lou, Z.Y. | | Deposit date: | 2012-07-15 | | Release date: | 2013-03-27 | | Last modified: | 2013-08-07 | | Method: | X-RAY DIFFRACTION (2.6 Å) | | Cite: | Structural basis for treating tumor necrosis factor alpha (TNFalpha)-associated diseases with the therapeutic antibody infliximab
J.Biol.Chem., 288, 2013
|
|
7M6I
 | |
7M6H
 | |
4I2X
 | | Crystal structure of Signal Regulatory Protein gamma (SIRP-gamma) in complex with FabOX117 | | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, CHLORIDE ION, FabOX117 heavy chain, ... | | Authors: | Nettleship, J.E, Ren, J, Stuart, D.I, Owens, R.J, Oxford Protein Production Facility (OPPF) | | Deposit date: | 2012-11-23 | | Release date: | 2013-12-18 | | Last modified: | 2023-09-20 | | Method: | X-RAY DIFFRACTION (2.48 Å) | | Cite: | Crystal structure of signal regulatory protein gamma (SIRP gamma) in complex with an antibody Fab fragment.
Bmc Struct.Biol., 13, 2013
|
|
4I13
 | |
7S0J
 | | Crystal structure of Epstein-Barr virus gH/gL targeting antibody 769B10 | | Descriptor: | 769B10 Fab Heavy chain, 769B10 Fab Light chain, GLYCEROL | | Authors: | Chen, W.-H, Kanekiyo, M, Cohen, J.I, Joyce, M.G. | | Deposit date: | 2021-08-30 | | Release date: | 2022-11-09 | | Last modified: | 2023-10-18 | | Method: | X-RAY DIFFRACTION (2.15 Å) | | Cite: | Epstein-Barr virus gH/gL has multiple sites of vulnerability for virus neutralization and fusion inhibition.
Immunity, 55, 2022
|
|
7S08
 | |
4LDO
 | | Structure of beta2 adrenoceptor bound to adrenaline and an engineered nanobody | | Descriptor: | (2S)-2,3-dihydroxypropyl (7Z)-tetradec-7-enoate, Camelid Antibody Fragment, L-EPINEPHRINE, ... | | Authors: | Ring, A.M, Manglik, A, Kruse, A.C, Enos, M.D, Weis, W.I, Garcia, K.C, Kobilka, B.K. | | Deposit date: | 2013-06-24 | | Release date: | 2013-09-25 | | Last modified: | 2023-09-20 | | Method: | X-RAY DIFFRACTION (3.2 Å) | | Cite: | Adrenaline-activated structure of beta 2-adrenoceptor stabilized by an engineered nanobody.
Nature, 502, 2013
|
|
4LDE
 | | Structure of beta2 adrenoceptor bound to BI167107 and an engineered nanobody | | Descriptor: | (2S)-2,3-dihydroxypropyl (7Z)-tetradec-7-enoate, 8-[(1R)-2-{[1,1-dimethyl-2-(2-methylphenyl)ethyl]amino}-1-hydroxyethyl]-5-hydroxy-2H-1,4-benzoxazin-3(4H)-one, Camelid Antibody Fragment, ... | | Authors: | Ring, A.M, Manglik, A, Kruse, A.C, Enos, M.D, Weis, W.I, Garcia, K.C, Kobilka, B.K. | | Deposit date: | 2013-06-24 | | Release date: | 2013-09-25 | | Last modified: | 2023-09-20 | | Method: | X-RAY DIFFRACTION (2.79 Å) | | Cite: | Adrenaline-activated structure of beta 2-adrenoceptor stabilized by an engineered nanobody.
Nature, 502, 2013
|
|
4LDL
 | | Structure of beta2 adrenoceptor bound to hydroxybenzylisoproterenol and an engineered nanobody | | Descriptor: | (2S)-2,3-dihydroxypropyl (7Z)-tetradec-7-enoate, 4-[(1R)-1-hydroxy-2-{[1-(4-hydroxyphenyl)-2-methylpropan-2-yl]amino}ethyl]benzene-1,2-diol, Camelid Antibody Fragment, ... | | Authors: | Ring, A.M, Manglik, A, Kruse, A.C, Enos, M.D, Weis, W.I, Garcia, K.C, Kobilka, B.K. | | Deposit date: | 2013-06-24 | | Release date: | 2013-09-25 | | Last modified: | 2023-09-20 | | Method: | X-RAY DIFFRACTION (3.1 Å) | | Cite: | Adrenaline-activated structure of beta 2-adrenoceptor stabilized by an engineered nanobody.
Nature, 502, 2013
|
|
4MWF
 | | Structure of Hepatitis C Virus Envelope Glycoprotein E2 core bound to broadly neutralizing antibody AR3C | | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, Envelope glycoprotein E2, ... | | Authors: | Kong, L, Wilson, I.A, Law, M. | | Deposit date: | 2013-09-24 | | Release date: | 2013-12-11 | | Last modified: | 2020-07-29 | | Method: | X-RAY DIFFRACTION (2.645 Å) | | Cite: | Hepatitis C virus e2 envelope glycoprotein core structure.
Science, 342, 2013
|
|
5MI0
 | | A thermally stabilised version of Plasmodium falciparum RH5 | | Descriptor: | MONOCLONAL ANTIBODY 9AD4, Reticulocyte binding-like protein 5,Reticulocyte binding protein 5 | | Authors: | Campeotto, I, Goldenzweig, A, Davey, J, Barfod, L, Marshall, J.M, Silk, S.E, Wright, K.E, Draper, S.J, Higgins, M.K, Fleishman, S.J. | | Deposit date: | 2016-11-27 | | Release date: | 2016-12-28 | | Last modified: | 2024-01-17 | | Method: | X-RAY DIFFRACTION (2.35 Å) | | Cite: | One-step design of a stable variant of the malaria invasion protein RH5 for use as a vaccine immunogen.
Proc. Natl. Acad. Sci. U.S.A., 114, 2017
|
|
6UYD
 | | Structure of Hepatitis C Virus Envelope Glycoprotein E2mc3-v1 redesigned core from genotype 1a bound to broadly neutralizing antibody AR3C | | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, Envelope glycoprotein E2, ... | | Authors: | Tzarum, N, Wilson, I.A, Zhu, J. | | Deposit date: | 2019-11-13 | | Release date: | 2020-04-22 | | Last modified: | 2023-10-11 | | Method: | X-RAY DIFFRACTION (1.897 Å) | | Cite: | Proof of concept for rational design of hepatitis C virus E2 core nanoparticle vaccines.
Sci Adv, 6, 2020
|
|
6UYM
 | | Structure of Hepatitis C Virus Envelope Glycoprotein E2mc3-v6 redesigned core from genotype 1a bound to broadly neutralizing antibody AR3C | | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, Envelope glycoprotein E2, ... | | Authors: | Tzarum, N, Wilson, I.A, Zhu, J. | | Deposit date: | 2019-11-13 | | Release date: | 2020-04-22 | | Last modified: | 2023-10-11 | | Method: | X-RAY DIFFRACTION (2.848 Å) | | Cite: | Proof of concept for rational design of hepatitis C virus E2 core nanoparticle vaccines.
Sci Adv, 6, 2020
|
|
6UYF
 | | Structure of Hepatitis C Virus Envelope Glycoprotein E2mc3-v1 redesigned core from genotype 6a bound to broadly neutralizing antibody AR3B | | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, Envelope glycoprotein E2, ... | | Authors: | Tzarum, N, Wilson, I.A, Zhu, J. | | Deposit date: | 2019-11-13 | | Release date: | 2020-04-22 | | Last modified: | 2023-10-11 | | Method: | X-RAY DIFFRACTION (2.06 Å) | | Cite: | Proof of concept for rational design of hepatitis C virus E2 core nanoparticle vaccines.
Sci Adv, 6, 2020
|
|
3MCG
 | |
6S34
 | |
8CWV
 | |
6NHA
 | | Crystal structure of SYNT001, a human FcRn blocking monoclonal antibody | | Descriptor: | 2-[N-CYCLOHEXYLAMINO]ETHANE SULFONIC ACID, Beta-2-microglobulin, IgG receptor FcRn large subunit p51, ... | | Authors: | Blumberg, R.S, Cheung, J, Mahmood, A, Gandhi, A.K. | | Deposit date: | 2018-12-21 | | Release date: | 2019-12-25 | | Last modified: | 2023-10-11 | | Method: | X-RAY DIFFRACTION (2.381 Å) | | Cite: | Blocking FcRn in humans reduces circulating IgG levels and inhibits IgG immune complex-mediated immune responses.
Sci Adv, 5, 2019
|
|
